top of page
PARTNERS WITH
Topotecan
Topoisomerase inhibitor
MECHANISM OF ACTION
Binds to DNA topoisomerase preventing re-ligation of cleaved DNA
MECHANISM OF KIDNEY INJURY
CLINICAL KIDNEY SYNDROME
myelosuppresion and diarrhea (acute and chronic)
CARDIOVASCULAR ADVERSE EFFECTS
LYTE ABNORMALITIES
RISK FACTORS
MITIGATION STRATEGIES
SUGGESTIONS
Avoid use in dialysis
NOTES/COMMENTS
eGFR 30-59 ml/min, 75-80% of usual dose
eGFR < 30 ml/min, 50-70% of usual dose
PHARMACOKINETICS
Molecular Weight
Volume of Distribution
Plasma Protein Binding
Metabolism
Bioavailability
Half-life elimination
Time to peak
Excretion
Renal, 20-68%
Dialyzable?
REF:
PATHOLOGY SLIDES:
ENTRY UPDATES:
Raad Chowdhury
United States
Sep 25, 2022
bottom of page